80.27 0.00 (0.00%)
After hours: 4:57PM EST
| Previous close | 81.33 |
| Open | 81.53 |
| Bid | 79.89 x 1000 |
| Ask | 80.79 x 900 |
| Day's range | 79.85 - 81.94 |
| 52-week range | 72.23 - 92.64 |
| Volume | 11,657,970 |
| Avg. volume | 9,523,268 |
| Market cap | 204.366B |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | 21.07 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.44 (3.00%) |
| Ex-dividend date | 12 Mar 2020 |
| 1y target est | N/A |
Merck Receives Complete Response Letter from the US FDA for Supplemental Biologics License Applications (sBLAs) for KEYTRUDA Six-Week Dosing Schedule
ERVEBO® (Ebola Zaire Vaccine, Live) Now Registered in Four African Countries, Within 90 Days of Reference Country Approval and WHO Prequalification
Merck’s KEYTRUDA in Combination with Chemotherapy Met Primary Endpoint of PFS as First-Line Treatment for Metastatic Triple-Negative Breast Cancer
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2019.
Merck to Focus on Key Growth Pillars Through Spinoff of Women’s Health, Trusted Legacy Brands and Biosimilars Products into New Company ("NewCo")
FDA Accepts For Review sNDA for RECARBRIO™ for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
Dr. Christine Seidman and Kathy Warden Elected to Merck Board of Directors
Merck Announces Second-Quarter 2020 Dividend
Lung Cancer Study Shows Barriers in Patient Access to Care in Europe
FDA Approves Merck’s DIFICID® (fidaxomicin) to Treat Clostridioides difficile in Children Aged Six Months and Older
FDA Accepts Regulatory Submission of sNDA for LYNPARZA in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review
FDA Accepts Regulatory Submission of sNDA for LYNPARZA as First-Line Maintenance with Bevacizumab in Advanced Ovarian Cancer & Grants Priority Review
FDA Approves Merck's KEYTRUDA® for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ
KEYTRUDA (pembrolizumab) in Combination w/Chemo Significantly Improved Progression-Free Survival Compared to Chemo Alone for Extensive Stage SCLC
Merck Establishes Strategic Oncology Collaboration with Taiho and Astex
Merck to Hold Fourth-Quarter and Full-Year 2019 Sales and Earnings Conference Call on February 5
Merck to Present at the 38th Annual J.P. Morgan Healthcare Conference